all classes of malignant tumors, after treatment with (or not applicable for) standard therapies for cancers
Conditions
Interventions
Alpha-beta T cells are intravenously administered almost every two weeks. Minimum dose of each injection will be more than one billion cells.
Sponsors
Center for Advanced Medical Innovation, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients to be included would satisfy all of the following conditions: (1) pathologically diagonized as and informed with malignant tumors, or if patients are diagonized as malignant tumors (such as liver , bile duct and pancreatic cancers) not pathologically but clinically i.e. with diagnostic imaging and laboratory finding, then treated with standard therapy (2) after treatment with (or not applicable for) standard therapies (3) age at the entry into this study is not less than 20 (4) outward patient (5) prognosis at the entry into this study is not less than 3 months and affordable with completion of 1 course immunotherapy (6 times injections) (6) fully informed of the treatment of this study with written consent
Exclusion criteria
Exclusion criteria: Patients to be excluded would satisfy any of the following conditions: (1) T cell- or NK cell-originated leukemia/lymphoma (2) serum positive for HTLV-1 and/or HIV antibody (3) organ- or allogeneic bone marrow-transplant recipients (4) Patients to be or wishing for pregnancy, or breast-feeding (5) Inward patients (6) Patientss who are regarded as inadequate for study enrollment by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival period (OS) for each class of malignant tumors | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival period (PFS), Disease-free survival period (DFS), response rate, efficience rate, disease control rate, side effetcs, etc for each class of malignant tumors | — |
Countries
Japan
Contacts
Public ContactTadafumi Iino ( or Shigeo Takaishi )
Center for Advanced Medical Innovation, Kyushu University Division of Advanced Cell Therapy
Outcome results
None listed